Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

11 evidence topics · 10 sources

Summary

In the Sequenced Treatment Alternatives to Relieve Depression trial, remission rates fell from 36.8% at step 1 to 13.0% at step 4, with higher relapse rates after more steps, and a reanalysis with the protocol-stipulated HRSD found a cumulative remission rate of 35.0% against the reported 67%. ICER's draft scope states that another antidepressant course succeeds much less often in TRD. Adjunctive atypical antipsychotics have a “greater side effect burden than antidepressant monotherapy”: one analysis reported akathisia with aripiprazole (NNH 4) and sedation with quetiapine (NNH 3), and one study found higher all-cause mortality with antipsychotic use (HR 1.21). Esketamine is dispensed and administered only in certified healthcare settings, with monitoring for at least 2 hours at each session, and ketamine and esketamine often require repeated visits for maintenance doses and have limited access in some regions. In one analysis, ketamine effects lasted no more than one week. After successful ECT, 51.1% of patients relapsed by 12 months on continuation pharmacotherapy, and ECT use is limited by stigma, general anaesthesia, and concern about cognitive effects. rTMS requires daily clinic visits, psychotherapy can be burdensome because of frequent visits, and access is limited because not all providers have adequate training, and VNS carries a greater than 5% chance of significant adverse events.